60. HepB containing 20 μg of HBsAg (hepatitis B surface antigen)
combined with HepA (HepA-HepB; Twinrix
®
) 3-dose series can be
used for primary vaccination of HIV-infected patients ≥12 years of
age (SR-M).*
61. Internationally adopted HIV-infected children who had prior doses
of OPV should receive a total of 4 doses of a combination of OPV
and IPV vaccines (SR-L).
62. HPV4 is recommended over bivalent human papillomavirus
vaccine (HPV2) because HPV4 prevents genital warts (SR-L),*
although there are no data on differences between the vaccines for
preventing cervical dysplasia in HIV-infected women.
Live Vaccines
63. HIV-exposed or -infected infants should receive rotavirus vaccine
according to the schedule for uninfected infants (SR-L).
64. HIV-infected patients should NOT receive LAIV (WR-VL).
65. MMR should be administered to clinically stable HIV-infected
children 1-13 years old without severe immunosuppression (SR-M)
and HIV-infected patients ≥14 years without measles immunity and
with a CD4 T-cell lymphocyte count of ≥200/mm
3
(WR-VL).
66. HIV-infected children with a CD4 T-cell percentage of <15% (SR-M)
or patients ≥14 years with a CD4 T-cell lymphocyte count of <200
cells/mm
3
should not receive MMR (SR-M).
67. HIV-infected patients should NOT receive quadrivalent MMR-
varicella vaccine (MMRV) (SR-VL).
68. Varicella-nonimmune, clinically stable HIV-infected patients age
1-8 years with ≥15% CD4 T-lymphocyte percentage (SR-H), age
9-13 years with ≥15% CD4 T-lymphocyte percentage (SR-VL), and
age ≥14 years with CD4 T-lymphocyte counts of ≥200 cells/mm
3
should receive VAR (SR-VL). The 2 doses should be separated by
≥3 months (SR-M).
11
